Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 8, 2021 - Issue 1
Submit an article Journal homepage
2,508
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment

Line Kølner-AugustsonCenter for Rare Lung Disease, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Aarhus, DenmarkCorrespondence[email protected]
View further author information
,
Thomas Skovhus PriorCenter for Rare Lung Disease, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Aarhus, DenmarkView further author information
,
Vibeke SkivildCenter for Rare Lung Disease, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Aarhus, DenmarkView further author information
,
Anette AalestrupCenter for Rare Lung Disease, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Aarhus, DenmarkView further author information
&
Elisabeth BendstrupCenter for Rare Lung Disease, Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Aarhus, DenmarkORCID Iconhttps://orcid.org/0000-0002-4238-6963View further author information
ORCID Icon
Article: 1853658 | Received 24 Jan 2020, Accepted 16 Nov 2020, Published online: 30 Nov 2020

References

  • Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1). DOI:https://doi.org/10.1186/s12931-018-0845-5
  • Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49(2):1601592.
  • Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1). DOI:https://doi.org/10.1186/s12931-018-0730-2
  • Lee HE, Myong JP, Kim HR, et al. Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis. 2016;20(7):978–984.
  • King TE, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–8.
  • Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):78.
  • Atkins CP, Gilbert D, Brockwell C, et al. Fatigue in sarcoidosis and idiopathic pulmonary fibrosis: differences in character and severity between diseases. Sarcoidosis, Vasc Diffus Lung Dis off J WASOG. 2016;33(2):130–138.
  • Mänty M, Rantanen T, Era P, et al. Fatigue and depressive symptoms in older people. J Appl Gerontol. 2014;33(4):505–514.
  • Avlund K, Schultz-Larsen K, Davidsen M. Tiredness in daily activities at age 70 as a predictor of mortality during the next 10 years. J Clin Epidemiol. 1998;51(4):323–333.
  • Ekmann A, Osler M, Avlund K. The predictive value of fatigue for nonfatal ischemic heart disease and all-cause mortality. Psychosom Med. 2012;74(5):464–470.
  • Sheth JS, Xia M, Murray S, et al. Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respir Med. 2019;148:6–12.
  • Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255–263.
  • Watt T, Groenvold M, Bjorner JB, et al. Fatigue in the Danish general population. Influence of sociodemographic factors and disease. J Epidemiol Community Health. 2000;54(11):827–833.
  • De Vries J, Michielsen H, Van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9(3). DOI:https://doi.org/10.1348/1359107041557048
  • De Kleijn WPE, De Vries J, Wijnen PAHM, et al. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011;105(9):1388–1395.
  • Hendriks C, Drent M, Elfferich M, et al. The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018;24(5). DOI:https://doi.org/10.1097/MCP.0000000000000496
  • Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
  • Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–583.
  • Milioli G, Bosi M, Poletti V, et al. Sleep and respiratory sleep disorders in idiopathic pulmonary fibrosis. Sleep Med Rev. 2014;26. DOI:https://doi.org/10.1016/j.smrv.2015.03.005
  • Tibblin G, Bengtsson C, Furunes B, et al. Symptoms by age and sex: the population studies of men and women in gothenburg, Sweden. Scand J Prim Health Care. 1990;8(1):9–17.
  • Horisberger A, Courvoisier D, Ribi C. The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study. Arthritis Res Ther. 2019;21(1). DOI:https://doi.org/10.1186/s13075-019-1864-4
  • Bråndal A, Eriksson M, Wester P, et al. Reliability and validity of the Swedish Fatigue Assessment Scale when self-administered by persons with mild to moderate stroke. Top Stroke Rehabil. 2016;23(2):90–97.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.